{"id":860552,"date":"2025-06-14T00:03:08","date_gmt":"2025-06-14T04:03:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/"},"modified":"2025-06-14T00:03:08","modified_gmt":"2025-06-14T04:03:08","slug":"prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/","title":{"rendered":"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims<\/b><\/p>\n<p class=\"bwalignc\"><i>For More Information, Visit <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SaveSinovac.com&amp;esheet=54276162&amp;newsitemid=20250613698243&amp;lan=en-US&amp;anchor=www.SaveSinovac.com&amp;index=1&amp;md5=b56a90d331981926961c5848169bb1c8\"><i>www.SaveSinovac.com<\/i><\/a><\/p>\n<p>HONG KONG&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPrime Success L.P., (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d or the \u201cCompany\u201d) with ownership of approximately 8% of the Company\u2019s outstanding shares, today issued the following letter in response to the Company\u2019s recent false and misleading claims relating to the upcoming Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) scheduled for July 8, 2025.<\/p>\n<p>\nThe full text of the letter is below and available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SaveSinovac.com&amp;esheet=54276162&amp;newsitemid=20250613698243&amp;lan=en-US&amp;anchor=www.SaveSinovac.com&amp;index=2&amp;md5=3afe7c69441f7d4f01f9e853bc8f3d51\">www.SaveSinovac.com<\/a>.<\/p>\n<p><b>Dear fellow Sinovac shareholders,<\/b><\/p>\n<p>\nPrime Success, L.P. (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d or the \u201cCompany\u201d), continues to be disappointed by the current Board\u2019s (\u201c1Globe Activist Board\u201d) distortion of the facts about what is at stake at the upcoming Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) scheduled for July 8, 2025. In our June 10 <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20250610033915%2Fen%2FPrime-Success-Sends-Letter-to-Sinovac-Biotech-Shareholders&amp;esheet=54276162&amp;newsitemid=20250613698243&amp;lan=en-US&amp;anchor=letter&amp;index=3&amp;md5=a669867d39661dde3a06c6f3e5979eef\">letter<\/a> we addressed several of the 1Globe Activist Board\u2019s misstatements and are taking the opportunity to remind all shareholders why the 1Globe Activist Board cannot be trusted:<\/p>\n<p><b>1. <span class=\"bwuline\">Prime Success is insisting that a dividend be distributed \u2013 for all shareholders<\/span><\/b><\/p>\n<p>\nThe 1Globe Activist Board\u2019s false comments are just not credible \u2013 why would any investor be against receiving a dividend? The 1Globe Activist Board wants you to believe that Prime Success is the reason that dividends have not been distributed, but we are not the Company and are not on the Board, and dividend distribution decisions are not ours to make. We can only continue to advocate on behalf of all shareholders that they should be made.<\/p>\n<p>\nUnder the leadership of a SAIF Partners IV L.P. (\u201cSAIF\u201d) nominated Board \u2014 composed of seasoned professionals with proven governance experience, deep operational insight, and a track record of building real, lasting value \u2014 we are confident that the pattern of internal conflict and ongoing litigation fueled by the 1Globe Activist Board can be broken, and shareholders can look forward to more future dividends. But that will not be possible with the 1Globe Activist Board in power as they have made clear they prioritize endless litigation over the Company\u2019s long-term success.<\/p>\n<p><b>2. <span class=\"bwuline\">The 1Globe Activist Board is deliberately baiting shareholders by setting the dividend distribution date for one day after the Special Meeting. We call upon the Company to make dividend distribution <\/span><i><span class=\"bwuline\">before<\/span><\/i><span class=\"bwuline\"> the Special Meeting<\/span><\/b><\/p>\n<p>\nThe 1Globe Activist Board deliberately set the dividend date for one day after the Special Meeting which creates the false impression that shareholders must vote for the incumbents to receive the dividends. But the upcoming Special Meeting will determine the Company\u2019s future direction and the long-term interests of all shareholders. We call on the 1Globe Activist Board to allow for a fair, <i>pro rata<\/i> distribution of dividends and to move the date of the dividend distribution to <b><i><span class=\"bwuline\">before<\/span><\/i><\/b> the Special Meeting so the meeting can refocus on its proper purpose: electing a competent Board.<\/p>\n<p><b>3. <span class=\"bwuline\">The 1Globe Activist Board distorts historic facts to aggrandize 1Globe and smear legitimate investors<\/span><\/b><\/p>\n<p>\nLet&#8217;s compare facts against rhetoric of the 1Globe Activist Board. Over the past seven years, what have we contributed to the Company?<\/p>\n<p>\nThe critical lifeline investments from Prime Success and Vivo Capital, LLC, combined with management\u2019s determined efforts, enabled Sinovac to seize a pivotal opportunity: the development of CoronaVac. This initiative ultimately resulted in the delivery of billions of doses to over 60 countries, generating substantial revenues while saving countless lives. Without the success of CoronaVac, there would not be any sizable dividend to distribute now.<\/p>\n<p>\nIn contrast, what has 1Globe done for the Company?<\/p>\n<p>\nIt has initiated multi-jurisdictional litigation against Sinovac, leading to a waste of company resources. The 1Globe Activist Board&#8217;s mischaracterization of 1Globe and Prime Success&#8217; relative contribution to Sinovac and its shareholders reveals its deeply partisan nature.<\/p>\n<p><b>4. <span class=\"bwuline\">Shareholders: looking forward, it\u2019s time to focus on what truly matters \u2013 the <i>future<\/i> of your investment in Sinovac<\/span><\/b><\/p>\n<p>\nSinovac needs a Board that will roll up its sleeves and run the business, guiding the Company forward on a stable, productive path. The slate put forward by SAIF, consisting of representatives from all shareholders owning more than 5% of the Company&#8217;s equity stake, many of whom possess deep industry experience, achieves exactly that.<\/p>\n<p>\nWe urge all shareholders to focus on the future and choose the leadership that will best secure our Company\u2019s success in the years to come. We look forward to continuing to make our case for change to our fellow shareholders and encourage them to wait for and read SAIF\u2019s proxy materials before voting for the Special Meeting on July 8, 2025.<\/p>\n<p>\nSincerely,<br \/>\n<br \/>Prime Success, L.P.<\/p>\n<p><b>About Prime Success, L.P.<\/b><\/p>\n<p>\nPrime Success is an investment vehicle established by Advantech Capital specifically to invest in Sinovac and Sinovac Life Sciences; Advantech Capital is a private equity fund established in 2016 with a focus on innovation-driven growth opportunities in China.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250613698243\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250613698243\/en\/<\/a><\/span><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Longacre Square Partners<br \/>\n<br \/>Dan Zacchei \/ Miller Winston<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:advantech@longacresquare.com\">advantech@longacresquare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Asia Pacific Hong Kong<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Asset Management Professional Services Finance<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims For More Information, Visit www.SaveSinovac.com HONG KONG&#8211;(BUSINESS WIRE)&#8211; Prime Success L.P., (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d or the \u201cCompany\u201d) with ownership of approximately 8% of the Company\u2019s outstanding shares, today issued the following letter in response to the Company\u2019s recent false and misleading claims relating to the upcoming Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) scheduled for July 8, 2025. The full text of the letter is below and available at www.SaveSinovac.com. Dear fellow Sinovac shareholders, Prime Success, L.P. (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860552","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims For More Information, Visit www.SaveSinovac.com HONG KONG&#8211;(BUSINESS WIRE)&#8211; Prime Success L.P., (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d or the \u201cCompany\u201d) with ownership of approximately 8% of the Company\u2019s outstanding shares, today issued the following letter in response to the Company\u2019s recent false and misleading claims relating to the upcoming Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) scheduled for July 8, 2025. The full text of the letter is below and available at www.SaveSinovac.com. Dear fellow Sinovac shareholders, Prime Success, L.P. (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d &hellip; Continue reading &quot;Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-14T04:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims\",\"datePublished\":\"2025-06-14T04:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/\"},\"wordCount\":879,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/\",\"name\":\"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-06-14T04:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/","og_locale":"en_US","og_type":"article","og_title":"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims - Market Newsdesk","og_description":"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims For More Information, Visit www.SaveSinovac.com HONG KONG&#8211;(BUSINESS WIRE)&#8211; Prime Success L.P., (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d or the \u201cCompany\u201d) with ownership of approximately 8% of the Company\u2019s outstanding shares, today issued the following letter in response to the Company\u2019s recent false and misleading claims relating to the upcoming Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) scheduled for July 8, 2025. The full text of the letter is below and available at www.SaveSinovac.com. Dear fellow Sinovac shareholders, Prime Success, L.P. (together with its affiliates, \u201cPrime Success\u201d or \u201cwe\u201d), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d &hellip; Continue reading \"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-14T04:03:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims","datePublished":"2025-06-14T04:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/"},"wordCount":879,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/","name":"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-06-14T04:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250613698243r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-success-responds-to-sinovac-biotechs-false-and-misleading-claims\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prime Success Responds to Sinovac Biotech\u2019s False and Misleading Claims"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860552"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860552\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}